Perilous Reversal Stock: Progenics Pharmaceuticals (PGNX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Progenics Pharmaceuticals ( PGNX) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Progenics Pharmaceuticals as such a stock due to the following factors:

  • PGNX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.7 million.
  • PGNX has traded 482,397 shares today.
  • PGNX is down 3.2% today.
  • PGNX was up 7.6% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PGNX with the Ticky from Trade-Ideas. See the FREE profile for PGNX NOW at Trade-Ideas

More details on PGNX:

Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. PGNX has a PE ratio of 121. Currently there is 1 analyst that rates Progenics Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Progenics Pharmaceuticals has been 950,200 shares per day over the past 30 days. Progenics has a market cap of $506.3 million and is part of the health care sector and drugs industry. The stock has a beta of 2.75 and a short float of 25.9% with 6.62 days to cover. Shares are up 3.4% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Oversold Small-Cap Biotech Names

3 Biotechs to Buy This Summer

What Poker Taught Me About Investing

What Poker Taught Me About Investing

4 Small-Cap Biotech Stars